
The European Union’s medicines regulatory agency on Wednesday is releasing the findings of its investigation into a possible link between AstraZeneca’s coronavirus vaccine and unusual blood clots, along with recommendations that could affect the use of an injection that is crucial to the global campaign against the pandemic.
Days ago, a senior European Medicines Agency (EMA) official said there was a causal link between AstraZeneca’s vaccine and blood clots that have been seen in dozens of people worldwide among the tens of millions who have received at least one dose of the shot.
Marco Cavaleri, head of health threats and vaccination strategy at the Amsterdam-based agency, said in remarks to the Roman daily Il Messaggero published Tuesday that it is becoming increasingly difficult to say there is no cause-and-effect relationship between AstraZeneca’s vaccines and the very rare cases of blood clots associated with low platelet levels.
Cavaleri acknowledged that the agency has not yet discovered how the vaccine causes these unusual side effects. The agency said its evaluation has not yet reached a conclusion and the review is continuing.
The EMA is studying in particular two types of unusual blood clots: one that appears in multiple blood vessels and another that occurs in a vein that drains blood from the brain. It also evaluates reports of people with low platelet levels, which means an increased risk of serious bleeding.
The EMA, the World Health Organization and various health authorities have repeatedly said that AstraZeneca’s vaccine is safe and effective and that the protection it provides against COVID-19 outweighs the comparatively small risks of blood clots.
